UNSPSC 51361507: Chloralodol or chlorhexadol

This classification denotes a hypnotic with the molecular formula C8H15Cl3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W8RD4N93R2, chemically known as 2-methyl-4-(2,2,2-trichloro-1-hydroxyethoxy)pentan-2-ol but generally known as chloralodol, which bears US NIH Compound Identifier 19094. European Medicines Agency schedules chloralodol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07465MIG. SMILES: CC(CC(C)(C)O)OC(C(Cl)(Cl)Cl)O.

UNSPSC 51361507 Chloralodol or chlorhexadol is a Commodity code that appears in state and local procurement records with minimal recent relevant activity. The three most recent opportunities posted under or near this code do not involve chloralodol or chlorhexadol procurement. Instead, they target naloxone and drug deactivation systems (Seminole County, Florida), direct-to-manufacturer prescription programs (Texas HHS Commission), and generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing (Minnesota Multistate Cooperative Purchasing Alliance). The code's nominal scope—a specific chemical compound used in pharmaceutical manufacturing or as an active ingredient—does not align with the actual procurement activity surfaced in recent state and local contract notices. State and local purchasing offices do not appear to be soliciting chloralodol or chlorhexadol as a distinct product line at this time.

The geographic spread of recent activity under codes in this family reflects purchases across Florida, Texas, and Minnesota through diverse issuing bodies including county health departments, state health and human services agencies, and multistate cooperative purchasing vehicles. Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) sought naloxone and drug deactivation systems on an annual basis with quarterly deliveries. The Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) gathered market intelligence on direct-to-manufacturer prescription fulfillment models. Minnesota's MMCAP RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) established contracts for generic pharmaceuticals and OTC products across state and local facilities. The mismatch between the code's nominal scope and recent solicitations signals that this UNSPSC classification is either deprecated, mislabeled in procurement systems, or used so rarely in state and local government that it does not surface meaningful recent opportunities for this specific compound.